American Journal of Biomedical Research
ISSN (Print): 2328-3947 ISSN (Online): 2328-3955 Website: https://www.sciepub.com/journal/ajbr Editor-in-chief: Hari K. Koul
Open Access
Journal Browser
Go
American Journal of Biomedical Research. 2021, 9(1), 19-23
DOI: 10.12691/ajbr-9-1-4
Open AccessArticle

Research Progress on the Correlation between PTEN and Tumors

Xiaohui Cui1, 2, Shufeng Du1, 2, Rongrong Li1, 2, Xiaoxia Jiang1, 2 and Taihua Wang1, 2,

1Shandong New Medicine Research Institute of Integrated Traditional and Western Medicine, Jinan, Shandong Province, 250101

2Interventional Hospital of Shandong Red Cross Society, Jinan, Shandong Province, 250101

Pub. Date: May 27, 2021

Cite this paper:
Xiaohui Cui, Shufeng Du, Rongrong Li, Xiaoxia Jiang and Taihua Wang. Research Progress on the Correlation between PTEN and Tumors. American Journal of Biomedical Research. 2021; 9(1):19-23. doi: 10.12691/ajbr-9-1-4

Abstract

PTEN is a tumor suppressor gene with dual specific phosphatase activity discovered after p53. and its deletion and mutation are closely related to the occurrence of a variety of malignant tumors. PTEN regulates cell proliferation, survival, and metabolism by inhibiting the activity of the PI3K/Akt signaling pathway, many components of which have been found to be involved in tumorigenesis. Although the mechanisms by which PTEN function is disrupted are diverse, the most frequently observed events are deletion of a single gene copy of PTEN. In this paper, the data relating to PTEN loss in some common tumour types and the related treatment of tumors are reviewed.

Keywords:
PTEN PI3K/Akt tumorigenesis treatment

Creative CommonsThis work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References:

[1]  Cristofano A Di, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell. 2000; 18; 100(4): 387-90.
 
[2]  Li J, Yen C, Liaw D, Podsypanina K, Bose S, Wang S I, et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 1997; 28; 275(5308): 1943-7.
 
[3]  Steck PA, Pershouse MA, Jasser SA, Yung WK, Lin H, Ligon AH, et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q 23.3 that is mutated in multiple advanced cancers. Nat Genet. 1997; 15(4): 356-62.
 
[4]  Eng C. PTEN: one gene, many syndromes. Hum Mutat. 2003; 22: 183-98.
 
[5]  Li HG, Liu FF, Zhu HQ, Zhou Xu, Lu J, Chang H et al. Association of PTEN gene polymorphisms with liver cancer risk. Int J Clin Exp Pathol; 2015; 1; 8(11): 15198-203. eCollection 2015.
 
[6]  Bermudez BM, Goulielmaki E, Papakonstanti EA. Focus on PTEN regulation. Front Oncol. 2015; 27; 5: 166.
 
[7]  Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012; 4; 13(5): 283-96.
 
[8]  Leslie NR, Bennett D, Gray A, Pass I, Hoang-Xuan K, Downes CP. Targeting mutants of PTEN reveal distinct subsets of tumour suppressor functions. Biochem J. 2001; 15; 357(Pt 2): 427-35.
 
[9]  Vazquez F, Ramaswamy S, Nakamura N, Sellers WR. Phosphorylation of the PTEN tail regulates protein stability and function. Mol Cell Biol. 2000; 20(14): 5010-8.
 
[10]  Torres J, Rodriguez J, Myers MP, Valiente M, Graves JD, Tonks NK et al. Phosphorylation-regulated cleavage of the tumor suppressor PTEN by caspase-3: implications for the control of protein stability and PTEN-protein interactions. J Biol Chem, 15; 278(33): 30652-60.
 
[11]  Torres J, Pulido R. The tumor suppressor PTEN is phosphorylated by the protein kinase CK2 at its C terminus. Implications for PTEN stability to proteasome-mediated degradation. J Biol Chem. 2001; 12; 276(2): 993-8.
 
[12]  Gil A, Andres-Pons A, Fernandez E, Valiente M, Torres J, Cervera J, et al. Nuclear localization of PTEN by a Ran-dependent mechanism enhances apoptosis: Involvement of an N-terminal nuclear localization domain and multiple nuclear exclusion motifs. Mol Cell Biol. 2006; 17(9): 4002-13.
 
[13]  Cristofano AD, Pesce B, Cordon-Cardo C, Pandolfi PP. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 1998; 19(4):348-55.
 
[14]  Suzuki A, de la Pompa JL, Stambolic V, Elia AJ, Sasaki T, del Barco Barrantes I,et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr Bio. 1988; 22; 8(21): 1169-78.
 
[15]  Podsypanina, K. Ellenson LH, Nemes A, Gu J, Tamura M, Yamada KM, et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc Natl Acad. Sci USA. 1999; 16; 96(4): 1563-8..
 
[16]  Di Cristofano A, Kotsi P, Peng YF, Cordon-Cardo C, Elkon KB, Pandolfiet PP. Impaired Fas response and autoimmunity in Pten+/− mice. Science. 1999; 24; 285(5436): 2122-5.
 
[17]  Song MS, Salmena L, Pandolfi PP. The functions and regulation of the PTEN tumour suppressor. Nat Rev Mol Cell Biol. 2012; 4; 13(5): 283-96.
 
[18]  Braccini L, Ciraolo E, Martini M, Pirali T, Germena G, Rolfo K, et al. PI3K keeps the balance between metabolism and cancer. Adv Biol Regul. 2012; 52(3): 389-405.
 
[19]  Maehama T, Dixon JE. The tumor suppressor,PTEN/MMAC1, dephosphorylates the lipid second messenger, phosphatidylinositol 3,4,5-trisphosphate. J Biol Chem. 1998; 29; 273(22): 13375-8.
 
[20]  Stambolic V, Suzuki A, de la Pompa JL, Brothers GM, Mirtsos C, Sasaki T, et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 1998; 2; 95(1): 29-39.
 
[21]  Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Yh, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell. 2010; 13; 18(1): 11-22.
 
[22]  Yuan TL, Cantley LC. PI3K pathway alterations in cancer: variations on a theme. Oncogene. 2008; 18; 27(41): 5497-510.
 
[23]  Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989; 1; 49(17): 4682-9.
 
[24]  Carnero A, Beach, DH. Absence of p21 WAF1 cooperates with c-myc in bypassing Ras-induced senescence and enhances oncogenic cooperation. Oncogene. 2004; 5; 23(35): 6006-11.
 
[25]  Morrison, DK, Cutler RE. The complexity of Raf-1 regulation. Curr Opin Cell Biol. 1997.
 
[26]  McFarlin DR, Gould MN. Rat mammary carcinogenesis induced by in situ expression of constitutive Raf kinase activity is prevented by tethering Raf to the plasma membrane. Carcinogenesis. 2003; 24(6): 1149-53.
 
[27]  McFarlin DR, Lindstrom MJ, Gould MN. Affinity with Raf is sufficient for Ras to efficiently induce rat mammary carcinomas. Carcinogenesis. 2003; 24(1): 99-105.
 
[28]  Lim KH, Counter CM. Reduction in the requirement of oncogenic Ras signalling to activation of PI3K/AKT pathway during tumour maintenance. Cancer Cell. 2005; 8(5): 381-92.
 
[29]  Bonneau D, Longy M. Mutations of the human PTEN gene. Hum Mutat. 2000; 16(2): 109-22.
 
[30]  Walker SM, Leslie NR, Perera NM, Batty IH, Downes CP. The tumour-suppressor function of PTEN requires an N-terminal lipid-binding motif, Biochem J. 2004; 15; 379(Pt 2): 301-7.
 
[31]  Trabelsi S, Chabc houb I, Ksira I, Karmeni N, Mama N, Kanoun S,et al. Molecular diagnostic and prognostic subtyping of gliomas in tunisian population. Mol Neurobiol. 2017; 54(4): 2381-2394.
 
[32]  Akyerli CB, Erson-Omay EZ, Oktay Y, Erson-Omay EZ, Oktay Y, Coşgun E,et al. Use of telomerase promoter mutations to mark specific molecular subsets with reciprocal clinical behavior in IDH mutant and IDH wild-type diffuse gliomas. J Neurosurg. 2018; 128(4): 1102-1114.
 
[33]  Depowski PL, Rosenthal SI, Ross JS. Loss of expression of the PTEN gene protein product is associated with poor outcome in breast cancer. Mod. Pathol. 2001; 14(7): 672-6.
 
[34]  Álvarez-Garcia V, Tawil Y, Wise HM, Leslie NR. Mechanisms of PTEN loss in cancer: It’s all about diversity. Semin Cancer Biol. 2019; 59:66-79.
 
[35]  Tabe Y, Tafuri A, Sekihara K, Yang H, Konopleva M. Inhibition of mTOR kinaseasa the rapeutic target for acute myeloidleukemia. Expert Opinionon Therapeutic Targets. 2017; 21(7): 705-714.
 
[36]  Cristofano AD, Ellenson LH. Endometrial carcinoma. Annu Rev Pathol. 2007; 2: 57-85.
 
[37]  Sun H, Enomoto T, Fujita M, Wada H, Yoshino K, Ozaki K, et al. Mutational analysis of the PTEN gene in endometrial carcinoma and hyperplasia. Am J Clin Pathol. 2001; 115(1): 32-8.
 
[38]  McConechy MK, Ding J, Senz J, Yang W, Melnyk N, Tone AA, et al. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles. Mod Pathol. 2014; 27(1): 128-34.
 
[39]  Merritt MA, Cramer DW. Molecular pathogenesis of endometrial and ovarian cancer. Cancer Biomark. 2010; 9(1-6): 287-305.
 
[40]  Yokota J, Kohno T. Molecular footprints of human lung cancer progression.Cancer Sci.2004; 95(3): 197-204.
 
[41]  Jamaspishvili T, Berman DM, Ross AE, Scher HI, Marzo AMD, Squire JA,et al. Clinical implications of PTEN loss in prostate cancer. Nat Rev Urol. 2018; 15(4): 222-234.
 
[42]  Lotan TL, Gurel B, Sutcliffe S, Esopi D, Liu W, Xu J, et al. PTEN protein loss by immunostaining: analytic validation and prognostic indicator for a high risk surgical cohort of prostate cancer patients. Clin Cancer Res. 2011; 15; 17(20): 6563-73.
 
[43]  Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature.2012; 18; 487(7407): 330-7.
 
[44]  Nassif NT, Lobo GP, Wu X, Henderson CJA, Morrison CD, Eng C, et al. PTEN mutations are common in sporadic microsatellite stable colorectal cancer. Oncogene. 2004; 15; 23(2): 617-28.
 
[45]  Blanco-Aparicio C, Pequeno B, Moneo V, Romero L, Leal JFM, Velasco J, et al. Inhibition of phosphatidylinositol-3-kinase synergizes with gemcitabine in low-passage tumour cell lines correlating with Bax translocation to the mitochondria. Anticancer Drugs. 2005; 16(9): 977-87.
 
[46]  Davies MA, Kim SJ, Parikh NU, Dong Z, Bucana CD, Gallick GE. Adenovira-mediated expression of MMAC/PTEN in hibitsproliferation and metastasis of human prostate cancer cells. Clinical Cancer Research. 2002; 8(6): 1904-14.
 
[47]  Tanaka M, Rosser CJ, Grossman HB. PTEN gene therapy induces growth inhibition and increases eff icacy of chemotherapy in prostate cancer. Cancer Detect Prey. 2005; 29(2): 170-4.
 
[48]  Rosser CJ, Tanaka M, Pisters LL, Tanaka N, Levy LB, Hoover DC, et a1. Adenovira1-mediated PTEN transgene expression sensitizes Bcl-2-expressing prostate cancer cells to radiation. Cancer Gene Ther. 2004; 11(4): 273-9.